A Phase 1 Double-blind, Dose-escalation, Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults in China

Trial Profile

A Phase 1 Double-blind, Dose-escalation, Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults in China

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Aug 2015

At a glance

  • Drugs Ad5 EBOV DNA vaccine (Primary)
  • Indications Ebola virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Tianjin CanSino Biotechnology
  • Most Recent Events

    • 06 Jun 2015 Results published in the Lancet.
    • 06 Jun 2015 Status changed from active, no longer recruiting to completed, as reported in The Lancet.
    • 06 Jun 2015 Primary endpoint has been met. (Specific anti-EBOV antibody responses to the Ebola Zaire vaccine (Ad5-EBOV).)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top